Lataa...
Development of a Genomic Signatures-Based Predictor of Initial Platinum-Resistance in Advanced High-Grade Serous Ovarian Cancer Patients
BACKGROUND: High grade serous ovarian cancer (HGSOC) is the most common subtype of ovarian cancer. Although platinum-based chemotherapy has been the cornerstone for HGSOC treatment, nearly 25% of patients would have less than 6 months of interval since the last platinum chemotherapy, referred to as...
Tallennettuna:
| Julkaisussa: | Front Oncol |
|---|---|
| Päätekijät: | , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Frontiers Media S.A.
2021
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7977004/ https://ncbi.nlm.nih.gov/pubmed/33747898 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.625866 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|